Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Multi-vitamin research

This article was originally published in The Tan Sheet

Executive Summary

Congressionally mandated study examining the relationship between daily vitamin usage and academic performance of at-risk children will begin in December and run through May 2004, The Healthy Foundation announced July 16. One thousand five hundred fourth-graders will be chosen at random from an urban school district in N.J. to receive either a daily placebo or vitamins provided by Tishcon Corp. Researchers will then evaluate results of a state-authorized, standardized exam, grade point averages, misbehavior and punctuality. Sen. Tom Harkin (D-Iowa) and Rep. Frank Pallone (D- N.J.) sponsored a $500,000 grant for the study in the FY 2002 Labor/HHS Appropriations bill (1"The Tan Sheet" Oct. 8, 2001, p. 15)...

You may also be interested in...

Vitamin Distribution, Research Funding Planned Through HHS Appropriations

Rep. Frank Pallone (D-N.J.) wants to include language in the HHS appropriations bill that would provide $6 mil. to help expand a national program that donates multivitamins to children at risk for malnutrition and funds research on the benefits of dietary supplements in children.

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts